1. Home
  2. IVDA vs ONCO Comparison

IVDA vs ONCO Comparison

Compare IVDA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

HOLD

Current Price

$0.24

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.82

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVDA
ONCO
Founded
2003
2018
Country
United States
United States
Employees
32
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IVDA
ONCO
Price
$0.24
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
323.4K
397.0K
Earning Date
05-12-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.09
52 Week High
$2.24
$6.73

Technical Indicators

Market Signals
Indicator
IVDA
ONCO
Relative Strength Index (RSI) 35.85 47.02
Support Level $0.23 $0.60
Resistance Level $0.34 $0.91
Average True Range (ATR) 0.02 0.10
MACD -0.01 -0.01
Stochastic Oscillator 9.13 37.34

Price Performance

Historical Comparison
IVDA
ONCO

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: